Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020118208 - A METHOD OF DETERMINING RISK FOR SKIN CANCER DEVELOPMENT AND SKIN CANCER THERAPEUTIC PREVENTION BY MEASURING PD-1/PD-L1 SIGNALING PATHWAY MEMBERS

Publication Number WO/2020/118208
Publication Date 11.06.2020
International Application No. PCT/US2019/064992
International Filing Date 06.12.2019
IPC
C07K 14/705 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C12N 5/00 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Applicants
  • ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA [US]/[US]
  • GEORGE MASON UNIVERSITY [US]/[US]
Inventors
  • CURIEL, Clara N.
  • BAKER, Amanda Fern
  • DICKINSON, Sally E.
  • PETRICOIN III, Emanuel F.
Agents
  • NGUYEN, Quan
Priority Data
62/776,88507.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) A METHOD OF DETERMINING RISK FOR SKIN CANCER DEVELOPMENT AND SKIN CANCER THERAPEUTIC PREVENTION BY MEASURING PD-1/PD-L1 SIGNALING PATHWAY MEMBERS
(FR) PROCÉDÉ DE DÉTERMINATION DU RISQUE DE DÉVELOPPEMENT DU CANCER DE LA PEAU ET DE PRÉVENTION THÉRAPEUTIQUE DU CANCER DE LA PEAU PAR MESURE DES MEMBRES DE LA VOIE DE SIGNALISATION PD-1/PD-L1
Abstract
(EN)
The present invention relates to a method of using family and/or regulatory members of the PD-1/PD-L1 pathway as predictive markers for risk of skin cancer development and as targets for therapeutic prevention of pre-malignant (or pre-cancerous) skin lesions and non-melanoma skin cancer (NMSC). This invention will allow for quantitative measurements of UV-induced expression of PD-1/PD-L1 signaling pathway family members (e.g., PD-1, PD-L1, PD-L2) and/or PD-1/PD-L1 regulatory factors including AP-1 and NFκB family members in skin tissue of individuals to determine an individual's 1) risk for skin cancer development and 2) appropriate prophylactic treatment strategy to prevent skin cancer development. This information will facilitate identification of those patients at risk for pre-malignant (or pre-cancerous) skin lesions or subsequent NMSC lesions who would benefit from a PD-1/PD-L1 pathway supressing therapy to prevent skin cancer development.
(FR)
La présente invention concerne un procédé d'utilisation des membres de la famille et/ou membres régulateurs de la voie PD-1/PD-L1 en tant que marqueurs prédictifs du risque de développement du cancer de la peau et en tant que cibles pour la prévention thérapeutique de lésions cutanées pré-malignes (ou pré-cancéreuses) et d'un cancer de la peau non mélanome (NMSC). Cette invention permet des mesures quantitatives de l'expression induite par les UV de membres de la famille de la voie de signalisation PD 1/PD-L1 (par exemple PD-1, PD-L1, PD-L2) et/ou de facteurs de régulation PD-1/PD-L1 comprenant des membres de la famille AP-1 et NFκB dans le tissu cutané d'individus pour déterminer 1) le risque individuel de développement du cancer de la peau et 2) une stratégie individuelle de traitement prophylactique appropriée pour prévenir le développement du cancer de la peau. Ces informations facilitent l'identification des patients à risque de lésions cutanées pré-malignes (ou précancéreuses) ou de lésions NMSC subséquentes qui pourraient bénéficier d'une thérapie de suppression de la voie PD-1/PD-L1 pour prévenir le développement du cancer de la peau.
Latest bibliographic data on file with the International Bureau